Genetically informed treatment framework for Inflammatory Bowel Disease (IBD)
Description of the granted funding
Already more than 1% of Finnish adult population has been diagnosed with Inflammatory bowel diseases (IBD). As chronic diseases, long-term pharmacotherapy is often used but it predisposes patients to adverse events. The longstanding dilemma in the clinic is how to provide personalized treatment for each patient. Genetic studies can guide such personalization as the treatment of IBD patients can often be adjusted by dosing, according to the status of genetic variants in certain key genes. In this project, we aim to generate a framework covering most commonly used medications in the treatment of IBD, later allowing gastroenterologists to make genetically informed decisions when considering a medication for a specific patient. We make use of unique FinnGen study aiming to collect the genomic information of 500,000 Finnish individuals in addition to of whole exome sequences of thousands of Finnish IBD patients to unravel the genetic determinants of the diverse drug responses.
Show moreStarting year
2020
End year
2024
Granted funding
Funder
Research Council of Finland
Funding instrument
Targeted Academy projects
Other information
Funding decision number
334229
Fields of science
Genetics, developmental biology, physiology
Research fields
Perinnöllisyystiede
Identified topics
genes, genetics